FMP

FMP

Enter

AZN - AstraZeneca PLC

photo-url-https://images.financialmodelingprep.com/symbol/AZN.png

AstraZeneca PLC

AZN

NASDAQ

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

68.77 USD

1.195 (1.74%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

26.62B

37.42B

44.35B

45.81B

54.07B

64.95B

78.01B

93.69B

112.53B

135.16B

Revenue %

-

40.58

18.53

3.29

18.03

20.11

20.11

20.11

20.11

Operating Cash Flow

4.8B

5.96B

9.81B

10.35B

11.86B

13.07B

15.69B

18.85B

22.64B

27.19B

Operating Cash Flow %

18.03

15.94

22.11

22.58

21.94

20.12

20.12

20.12

20.12

Cap Ex

-2.61B

-2.2B

-2.57B

-3.78B

-4.59B

-4.96B

-5.96B

-7.16B

-8.6B

-10.33B

Cap Ex %

-9.79

-5.88

-5.8

-8.25

-8.48

-7.64

-7.64

-7.64

-7.64

Free Cash Flow

2.19B

3.76B

7.24B

6.57B

7.28B

8.11B

9.74B

11.69B

14.04B

16.87B

Weighted Average Cost Of Capital

Price

68.77

Beta

Diluted Shares Outstanding

12.5B

Costof Debt

5.59

Tax Rate

After Tax Cost Of Debt

4.52

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

30.11B

Total Equity

859.84B

Total Capital

889.95B

Debt Weighting

3.38

Equity Weighting

96.62

Wacc

4.91

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

26.62B

37.42B

44.35B

45.81B

54.07B

64.95B

78.01B

93.69B

112.53B

135.16B

Operating Cash Flow

4.8B

5.96B

9.81B

10.35B

11.86B

13.07B

15.69B

18.85B

22.64B

27.19B

Cap Ex

-2.61B

-2.2B

-2.57B

-3.78B

-4.59B

-4.96B

-5.96B

-7.16B

-8.6B

-10.33B

Free Cash Flow

2.19B

3.76B

7.24B

6.57B

7.28B

8.11B

9.74B

11.69B

14.04B

16.87B

Wacc

4.91

4.91

4.91

4.91

4.91

Pv Lfcf

7.73B

8.85B

10.13B

11.59B

13.27B

Sum Pv Lfcf

51.57B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

4.91

Free Cash Flow T1

17.21B

Terminal Value

591.56B

Present Terminal Value

465.53B

Intrinsic Value

Enterprise Value

517.1B

Net Debt

24.63B

Equity Value

492.47B

Diluted Shares Outstanding

12.5B

Equity Value Per Share

39.39

Projected DCF

39.39 -0.746%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep